

## Press release

Montpellier, September 24, 2020

### **AxLR and MedXCell NKar sign two operating contracts**

Located in the incubator of the Institute of Regenerative Medicine and Biotherapies (IRMB) at CHU-Saint-Éloi in Montpellier, MedXCell NKar promotes research (NKab technology) resulting from a maturation program supported by SATT AxLR. In this context, MedXCell NKar has signed two operating contracts with SATT AxLR for the development and commercial exploitation of the NKab technology.

First, MedXCell NKar will develop drug candidates in oncohematology. Secondly, a wider range of therapeutic indications will be addressed by applying the technology to target solid tumors.

MedXCell NKar is a Montpellier biotech co-founded in March 2020 by the company MedXCell SA (Switzerland), researchers from the IRMB (Christian Jorgensen, Martin Villalba and Javier Hernandez) and researchers from the Montpellier Cancer Research Institute (IRCM) (Pierre Martineau and Bruno Robert).

The SATT (Technology Transfer Acceleration Company) AxLR is one of 13 companies operating in the country whose activity concerns economic development in the high technology sector from the scientific production of public research. [www.axlr.com](http://www.axlr.com)

MedXCell NKar contact:  
Marc CRITON  
+ 33 06 30 19 87 56  
[marc.criton@medxcell-science.com](mailto:marc.criton@medxcell-science.com)

SATT AxLR contact:  
Franck-Léopold Erstein  
+ 33 06 07 28 21 43  
[fle-externe@axlr.com](mailto:fle-externe@axlr.com)